Rahme Elham, Pettitt Dan, LeLorier Jacques
McGill University and McGill University Health Centre, Montreal, Quebec, Canada.
Arthritis Rheum. 2002 Nov;46(11):3046-54. doi: 10.1002/art.10604.
Acetaminophen is recommended as initial therapy for patients with arthritis, particularly those at increased risk of nonsteroidal antiinflammatory drug (NSAID)-induced gastrointestinal (GI) side effects. However, higher doses of acetaminophen inhibit prostaglandin synthesis and have been associated with GI events. This study was undertaken to compare the observed and adjusted rates of GI events (hospitalizations, ulcers, dyspepsia, GI prophylaxis) occurring with higher versus lower doses of acetaminophen.
This was a retrospective cohort study of subjects ages >or=65 years who received a prescription for acetaminophen or NSAID between 1994 and 1996. Pharmaceutical and medical records were reviewed for 1 year of historical data prior to the index prescription of acetaminophen or non-aspirin NSAID. Risk factors for GI events were identified based on the historical data. To further control for bias, patients were categorized by propensity score (the likelihood of receiving acetaminophen, given defined risk factor values). Records were then reviewed for the duration of the index prescription or 30 days, whichever was less, to generate data on the occurrence of GI events. Determinants of acetaminophen utilization were identified using logistic regression, and rates of GI events for each therapy were examined using Poisson regression analyses, controlling for duration of exposure, individual risk factors, and propensity scores.
The study included 26,978 patients in the NSAID cohort and 21,207 in the acetaminophen cohort. Determinants of acetaminophen utilization compared with NSAIDs (odds ratio [95% confidence interval]) included recent hospitalization (8.6 [7.7-9.5]), concomitant anticoagulation therapy (3.2 [2.7-3.8]), age >85 years (2.3 [2.1-2.4]), and history of prior GI events, especially those requiring hospitalization (14.6 [11.7-18.7]). Unadjusted rates of GI hospitalization, ulcer, and dyspepsia were higher for patients in the acetaminophen cohort than for those in the NSAID cohort. The occurrence of GI events in acetaminophen-treated patients was dose dependent, with rate ratios (compared with high-dose NSAIDs and adjusted for risk susceptibility) ranging from 0.6 (95% confidence interval 0.5-0.7) for <or=650 mg/day to 1.0 (0.9-1.1) for >3,250 mg/day.
In this cohort, acetaminophen utilization is more common in patients at higher risk of GI events. After adjustment for risk susceptibility, patients receiving higher doses of acetaminophen have higher rates of GI events compared with those receiving lower doses.
对关节炎患者,尤其是那些非甾体抗炎药(NSAID)引起胃肠道(GI)副作用风险增加的患者,推荐对乙酰氨基酚作为初始治疗药物。然而,较高剂量的对乙酰氨基酚会抑制前列腺素合成,并与胃肠道事件有关。本研究旨在比较较高剂量与较低剂量对乙酰氨基酚引发的胃肠道事件(住院、溃疡、消化不良、胃肠道预防用药)的观察发生率和校正发生率。
这是一项回顾性队列研究,研究对象为年龄≥65岁、在1994年至1996年间接受对乙酰氨基酚或NSAID处方的患者。对在对乙酰氨基酚或非阿司匹林NSAID索引处方前1年的历史数据进行药学和病历审查。根据历史数据确定胃肠道事件的危险因素。为进一步控制偏倚,根据倾向评分(给定定义的危险因素值时接受对乙酰氨基酚的可能性)对患者进行分类。然后审查索引处方期间或30天(以较短者为准)的记录,以生成胃肠道事件发生的数据。使用逻辑回归确定对乙酰氨基酚使用的决定因素,并使用泊松回归分析检查每种治疗的胃肠道事件发生率,同时控制暴露时间、个体危险因素和倾向评分。
该研究纳入了26978例NSAID队列患者和21207例对乙酰氨基酚队列患者。与NSAIDs相比,对乙酰氨基酚使用的决定因素(比值比[95%置信区间])包括近期住院(8.6[7.7 - 9.5])、同时进行抗凝治疗(3.2[2.7 - 3.8])、年龄>85岁(2.3[2.1 - 2.4])以及既往胃肠道事件史,尤其是那些需要住院治疗的事件(14.6[11.7 - 18.7])。对乙酰氨基酚队列患者的胃肠道住院、溃疡和消化不良的未校正发生率高于NSAID队列患者。对乙酰氨基酚治疗患者的胃肠道事件发生呈剂量依赖性,率比(与高剂量NSAIDs相比并根据风险易感性校正)范围为:每日剂量≤650mg时为0.6(95%置信区间0.5 - 0.7),每日剂量>3250mg时为1.0(0.9 - 1.1)。
在该队列中,胃肠道事件风险较高的患者更常使用对乙酰氨基酚。在对风险易感性进行校正后,接受较高剂量对乙酰氨基酚的患者与接受较低剂量的患者相比,胃肠道事件发生率更高。